Clinical Trials

UC Davis Cancer Center Renews Prestigious NCI Designation
Research & Development UC Davis Cancer Center Renews Prestigious NCI Designation

In addition to the recent NCI renewal, the UC Davis Medical Center has maintained its ranking as the top hospital in the Sacramento area for fifteen consecutive years according to national reports. This sustained excellence reached a new milestone today as the National Cancer Institute officially

Can Upadacitinib Redefine the Regulatory Path for Vitiligo?
Research & Development Can Upadacitinib Redefine the Regulatory Path for Vitiligo?

Historical failures in the vitiligo pipeline, such as the cancellation of the AC##4 trial in 2016, highlight the difficulty of establishing a global site network. The recent publication of the Viti-Up Phase 3 clinical trial results in The Lancet marks a transformative moment for dermatologic

Can a Common Drug Prevent Triple-Negative Breast Cancer?
Research & Development Can a Common Drug Prevent Triple-Negative Breast Cancer?

When levels of miR-342 drop, the E2F genetic pathway is unleashed, signaling disseminated cancer cells to begin the rapid multiplication required to form tumors. This mechanism serves as a terrifying catalyst for triple-negative breast cancer, a subtype that has historically defied the precision

Bioengineered Conduits Show Promise for Coronary Bypass Surgery
Research & Development Bioengineered Conduits Show Promise for Coronary Bypass Surgery

A major hurdle in cardiac surgery is the compliance mismatch between stiff artificial tubes and flexible arteries, which creates turbulent blood flow and eventual graft blockage. This fundamental discrepancy has long prevented the widespread adoption of synthetic bypass grafts, as the sudden change

Will the FDA Approve Deramiocel for Duchenne Muscular Dystrophy?
Research & Development Will the FDA Approve Deramiocel for Duchenne Muscular Dystrophy?

For the 15,000 Americans living with Duchenne muscular dystrophy, the three-month regulatory delay represents a critical window where irreversible physical decline remains a constant threat. This extension, moving the target decision date from August to November 22, 2026, occurred after the Food

How Is Tech Transforming Biopharmaceutical Innovation?
Tech & Innovation How Is Tech Transforming Biopharmaceutical Innovation?

The convergence of legacy manufacturing expertise and cutting-edge molecular platforms is fundamentally transforming the current biopharmaceutical landscape. This paradigm shift marks the end of an era defined by slow, incremental improvements and the beginning of a highly synchronized digital age.

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later